Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
January 31, 2024 at 11:43 AM EST
Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety or efficacy concerns."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.